Ojaswita, presently develops content for page125.org and a number of other similar platforms. Endowed with a prior experience of being a Technical Engineer, she now writes articles pertaining to business trends and the latest industry news. That apart, she loves to listen to music, craft, and cook in her leisure time. She can be contacted at- [email protected] | https://twitter.com/ojaswita_k
The American company will be paying millions to CytoReason for its unparalleled models. CytoReason, the Israel based machine learning company, that is credited for developing immune system cell-centered models that necessarily aid in drug discovery, recently entered a collaboration with American pharmaceutical corporation, Pfizer Inc. …
SIRION Biotech GmbH, a global leader in viral vector-based gene delivery technologies, has reportedly inked a collaboration contract and license with Denali Therapeutics, a biopharma firm which has developed a wide range of product candidates for treating neurodegenerative diseases. According to FierceBiotech, the two firms …
The Canadian cannabis firm Aphria Inc. has reportedly revealed to have concluded the acquisition of a major Germany-based importer and distributor of pharmaceutical products, CC Pharma GmbH. As per trusted sources, Aphria Inc. has paid €18.92 million in cash to the former stakeholders of CC …
Pharmaceutical major Lupin has made it to the headlines upon attaining the approval from the U.S. Food and Drug Administration for selling its Lurasidone Hydrochloride tablets, used to treat schizophrenia, in the American market. The approved product is a generic form of Sunovion Pharmaceuticals’ Latuda …
Vital Therapies, Inc., a biotechnology company based in California, has reportedly entered into a definitive collaboration agreement with Immunic AG, a Germany-based private clinical-stage biotechnology company. Under the terms of the agreement, Vital Therapies is expected to purchase all the outstanding shares in Immunic in …
Paragon Genomics, Inc., has recently announced a worldwide partnership with the subsidiary of BGI Group, MGI Tech Co., Ltd. Apparently, MGI would be distributing the CleanPlex® NGS Panels from Paragon Genomics for using them with the sequencing platforms of MGI around the world, except the …
In a recent turn of events, Merck & NGM Biopharmaceuticals Inc. jointly declared that Merck is reportedly exercising its options to license its NGM313 drug that is presently being examined for treating nonalcoholic steatohepatitis as well as type 2 diabetes. As per trusted sources, this …
Biotech firm Merus N.V. has announced that the company has agreed to provide an exclusive license to Betta Pharmaceuticals Co. Ltd. for developing and commercializing Merus Biclonics® MCLA-129 in China. Under the terms of the agreement, Merus would retain all the rights outside of China …
Biotechnology firm Cybrexa Therapeutics, that was developing a new class of cancer therapeutics via its tumor targeting platform alphalex™, has recently announced that the company chose CBX-11 as the leading clinical development candidate for treating patients with various types of solid tumors. Apparently, the company …
